StemCell Therapy

RINER Dogs and cats may not have to worry about COVID-19, but the pandemic viral infection is changing how some veterinarians practice.

At Riner Animal Hospital on Thursday, that meant Bear the black lab got his vaccines in the clinic while his ride, Joe Richmeier, sat in his truck in the parking lot. And Bear got a little walk from his vet, Dr. Lindsey Mabe, who brought the 1-year-old canine outside when his appointment was over.

Its all part of the new way the clinic handles patient care. For now, animal patients come inside, but their owners dont. All communication and payment is done in the parking lot or by phone.

Were really just trying to take every precaution to prevent exposure, Mabe said. And the new service reduces the need to constantly sanitize the waiting room. That allows the staff to conserve cleaning supplies that are already in short supply.

I really appreciate them doing that, Richmeier said. Im sure its inconvenient.

Mabe said its a little more work for the staff but worth it for everyones safety.

Dr. Richard Wright, practice owner, said he implemented the procedures on Tuesday at the request of his staff. The change came after Gov. Ralph Northam announced new guidelines to slow the spread of coronavirus in the state.

Northam announced Monday that gatherings of more than 10 people, including in most places of business in the state, are prohibited, and people with elevated risk, such as the elderly and those with chronic health conditions, are asked to voluntarily quarantine themselves.

So far in Virginia, more than 1,900 people have been tested for the novel coronavirus and at least 117 cases have been confirmed as of midday Friday, including one in Botetourt County, according to the Virginia Department of Health. Two people have died in the state, and at least 19 have been hospitalized.

The changes at Riner help the clinic comply with guidelines to slow the spread.

Its not unusual to have up to 10 people in the waiting room all clustered together, and thats not good, Wright said. If the owner wants to hold their dog, youre looking in the dogs eyes, and theres a lot of close contact there.

So far clients have been positive about the change, he said.

Its a great idea, said Rick Barrow, who came to the clinic on Thursday with his wife, Deb, to pick up prescription food for their cat, Izzy. Everybodys got to be safe.

The Virginia-Maryland College of Veterinary Medicines teaching hospital in Blacksburg was among the first veterinary practices to institute a drop-off-only policy starting on March 13, director Terry Swecker said. It applies to small and large animal clients.

Were big, meaning we have a lot of people, Swecker said. Im trying to protect people, both my people and the clients.

As a 24-hour, seven-day-a-week operation with dozens of medical and other support staff, faculty, students and practitioners potentially on site at any given time, preventing coronavirus infection was a particular concern, Swecker said.

Policies meant to minimize the number of staff and clients on site were formed with advice from the colleges public health experts, Swecker said.

Veterinary students were recently sent home to complete their semesters remotely, and the hospital is working to tailor its staffing to three priority areas: emergency services for all cases where the animals life is in danger, care of existing patients with conditions such as cancer and existing clients with cases that require timely treatment.

Appointments for vaccinations and other lower priority services, as well as enrolling new patients who need those nonemergency services will be delayed until the COVID-19 threat passes, Swecker said.

His advice to all clients: Call ahead and be prepared to talk about your case on the phone and to provide photos and even videos of the problem. And if the animal needs to be seen at the hospital, be prepared to drop it off, he said.

But most private practice clinics so far have made drop-off services optional.

On Monday, Companion Animal Clinic in Blacksburg implemented an optional limited contact appointment system for clients who want it, practice manager Sarah Perdue said. On Thursday, they had five such appointments.

Were into the unknown at this particular point, so we want everyone to have the option to feel comfortable, but for their pets to still receive care, Perdue said.

So far, the majority of clients have wanted regular appointments, she added. But that could change if coronavirus begins to spread in the New River Valley.

Roanoke Animal Hospital also is offering drop-off and other limited contact options, but clients have so far shown limited interest in them, Dr. Thomas Blaszak said.

Were cleaning nonstop to make sure if it [coronavirus] does at all step into our hospital, hopefully were killing it before it goes anywhere else, Blaszak said. The hospital also has asked staff members who have traveled recently to self-quarantine for 14 days.

Worldwide, more than 250,000 COVID-19 cases have been confirmed as of Friday. More than 11,000 people have died.

Excerpt from:
Dogs and cats leaving owners in the car - Roanoke Times

Adaptability in the age of COVID-19 is coming in the way of telemedicine.

Over the past several weeks, Oregon leaders have announced numerous, increasingly stringent orders around social distancing to help prevent the spread of COVID-19. Earlier this month, Gov. Kate Brown banned groups over 250. She narrowed that this week, banning groups of over 25. Hospitals and nursing care facilities have banned visitors all together.

Enter a lot more telemedicine.

The clinic will continue to provide in-person visits for newborns and for well-child checks for kids two and a half and undervisits that often include immunizations and monitoring developmental milestones that providers must do in person, COPA stated Friday. (Updated 3/21, 5:30pm: the original version of this story stated providers "can't" do those visits; that was inaccurate.)

Like other health care providers faced with supply chain disruptions, preserving PPEs is definitely a thing.

"COPA is conserving all our PPE supplies using multiple methods to ensure that our current supplies last as long as possible," Clausen wrote.

"The Oregon Veterinary Medical Examining Board issued a statement saying that says we can provide telemedicine to our patients," Maas said. "We are taking it seriously. We have already, for the last two weeks, have been anticipating a need for PPE, and conserving and recycling and reusing whenever possibleautoclaving it when we can, so we don't burn through one per patient. Because of that, we can still be open and still do the care we need for our patients."

Maas said his supplies of PPE are adequate for his team, but that they don't have a stockpile.

"I've responded to the emergency task forcefor things like anaesthesia, we will have that available for them in a time of need," he said.

"Before this throwaway society, we used to have cloth masks. We have a couple employees now doing that, who have seamstress skills."

"While telemedicine is still very much in its infancy, these new health care platforms have the potential to solve some of the most persistent problems faced by rural inhabitants," the Oregon Health Sciences University's Oregon Office of Rural Healthdetailed on its web page. Part of the office's purview is Project ECHO, which focuses not only on expanding telemedicine, but on using it to help health care providers in rural areas get the continuing education credits they need to maintain or advance their careers. "There are certainly limitations as to what telemedicine can accomplish, but for populations with limited access to health care, a little has the potential to go a long way."

Read the original:
A Pivot to Telemedicine | Local News | Bend - The Source Weekly

By DR JOSEPH MUGACHIAMore by this Author

Laboratory testing in both veterinary and human medical practice is a crucial ingredient of disease diagnosis. It is nowadays considered the gold standard for best practice in health services.

Incidentally, just like in other areas of medical practice, the analysis reports sometimes may be inaccurate and lead to improper treatment or management of a disease.

In veterinary medicine, such results, if not detected early, may result in improper and expensive treatment. The disease may escalate, cause death to the animal and unnecessary loss to the farmer.

You may recall last month (Seeds of Gold, February 19), I shared a black quarter case in a cow where I had submitted samples for laboratory analysis. I have since received the lab report.

Unfortunately, the test results were completely out of sync with my post-mortem (PM) findings. Such results cannot be considered for confirming the diagnosis of the problem.

In veterinary practice, PM observation, testing for disease confirmation in the lab is the gold standard for diagnosis of diseases in the field.

Most causes of death leave tell-tale changes in the body that inform the doctor on the disease and cause of death.

Laboratory testing, on the other hand, seeks to identify the agent or agents that caused the disease and death.

Post-mortem findings are more likely to be erroneous due to the doctors inadequate knowledge and experience than laboratory results.

This is because laboratory tests follow laid down protocols that use various standardised materials and equipment. PM examination is based on visual observations by the doctor. However, experienced doctors become PM diagnostic machines and give highly accurate diagnoses in most cases.

A good veterinary doctor should always express their sentiments in questionable laboratory test results and engage the facility to try and understand the source of the error.

If the various professionals involved in the diagnosis and laboratory testing transparently engage, they will always confirm the source of the error.

I found myself contesting the results I received from the laboratory on the black quarter case. My two intern doctors, Eddy and Joyce, were the first to notice the anomalies when they received the results on email.

Joyce was on duty regarding laboratory issues that day. She discussed with Eddy and they informed me the results did not look right.

The laboratory had suggested Daisy died of a bacterial infection. They said they isolated Corynebacteria species that were resistant to most drugs used in animal treatment.

I had no problem with the resistance findings as the bacteria species is notorious for drug resistance. My problem was with the bacteria family apparently isolated from my samples.

The laboratory test report was completely inconsistent with the PM findings. By all counts, there was no chance in the universe that the bacteria could cause sudden death with blackening of tissues and gas accumulation under the skin.

You see, most disease-causing microorganisms, including viruses, have unique footprints that they exhibit during infection and also by the time the animal dies.

That is why an animal health service provider in most cases diagnoses a disease and treats your animal without taking samples to the laboratory. Many farmers are witnesses that most of their animals recover after such treatment.

My PM findings had shown Daisy had died of black quarter whose signs of sickness and death I explained fully in the article.

Corynebacteria species commonly cause cattle diseases but their main footprint is production of pus in boils or mastitis.

The only time members of this bacterial group could cause sudden death is if the germs formed a large abscess on a major blood vessel and caused it to burst.

This would cause the animal to quickly bleed to death. I have only seen such abscesses in the lungs of cattle on three occasions in the entire course of my practice.

Daisy had no abscess in the body but had evident areas of severe tissue blackening in the heavy muscles of the neck and shoulders.

The cow also had heavy accumulation of a foul-smelling gas under the skin. It is only some members of the Clostridium species of bacteria that are known to have these signature effects.

Therefore, the difference in the signs of diseases caused by the two bacterial species and the PM findings leave no room for confusion.

I called the doctor who signed off the report in the lab and expressed my disagreement with the results. I sent her the full post-mortem report, including photographic evidence. She was in agreement that something went wrong and would investigate.

There are many reasons why a laboratory can return inaccurate test results. Most of the causes are human errors because majority of laboratory tests are automated.

The most common errors are those related to sample recording, often called paper work mix-ups. Once a sample is submitted to the laboratory, it is given a lab number and comprehensive recording to fit with the testing and reporting protocol. Erroneous recording may invalidate the whole testing process and results.

There are also procedural mistakes where the sample may get contaminated with other microorganisms because of inappropriate handling. Faulty equipment calibration or choice of the wrong test may also cause fatal errors and unacceptable results.

Sometimes the circumstances of the animal at the time of sample collection may also affect the test results. For instance, a milk sample taken from an animal under treatment may give incoherent test results.

Such milk may show mastitis to be caused by fungi while in reality, the fungi would have grown because of severe suppression of bacteria by antibiotics used for treatment.

If the submitting doctor provides insufficient information to the laboratory such as incomplete set of clinical signs observed in sick animals or post-mortem findings, the laboratory could make a choice of an inappropriate test and return erroneous results.

Finally, there are test results that could be false, negative or positive. These are mainly tests for the immune reaction of the animal body.

They are called immunological tests. Vaccinated animals may show false positive results while those with a weak immune system may show false negative results.

Continued here:
Vet on call: Beware, not all laboratory results are free of errors - Daily Nation

The COVID-19 outbreak continued to drastically affect the lives of local residents this past week, with schools cancelling classes for four weeks, universities moving fully online for the rest of the semester, and bars and restaurants being forced to close dining rooms and only offer carry-out and delivery services.

The number of confirmed cases of the coronavirus have soared in the past week, with a total of 68 in Iowa, including the first confirmed case in Story County, the governors announced Saturday.

Residents have been told to work remotely from home if they can, restrict gatherings to groups of no more than 10, and churches have canceled services, with many offering livestream service to parishioners. CyRide is limiting the number of riders on each bus to nine.

The changes we saw this past week left many residents and local business leaders stunned.

You can prepare for somethings, you can prepare for expenses that you know are coming, but instances like this honestly you really only have a matter of weeks to prepare, Andy McCormick, the owner of Torrent Brewing Company in Ames said.

On Tuesday morning, Gov. Kim Reynolds declared a state of emergency, ordering the closing of bars, restaurants, movie theaters, casinos, places of mass gatherings and senior citizen and adult day care centers as a response to the continued spread of COVID-19.

Right now were shocked, said Justin Kabrick, the owner of Dublin Bay Bar & Grill, which canceled its popular St. Patricks Day celebration.

Many churches have gone to streaming platforms such as Facebook live last Sunday, in what some pastors called an unprecedented event.

Its a wild time Im trying to think of how to put it into words, said Mark Vance, the lead pastor at Cornerstone Church. This is unlike any situation Ive ever had to try and lead through in my time in ministry, which is over a decade, and its something we havent seen in generations in the church.

St. Cecilias Catholic Church is not moving towards online streaming services, but live streams of the Archbishop of the Archdiocese of Dubuque will be available as well as channel 23s showing of Sunday mass, which is available on any TV that has an HD antenna, Father Jim Secora said.

Local fitness centers, public offices such as City Hall, county offices and the Ames Community Center have also been shut down until further notice. Even North Grand Mall has been affected as some of its stores have closed.

Iowa State University announced Wednesday that it was moving all classes to online only the rest of the semester and canceling spring commencement.

We regret that Iowa State must also cancel spring commencement ceremonies for undergraduates, graduate students, and veterinary medicine students, ISU wrote in an email to university students and community on Wednesday. Campus leaders are working on plans for a live-streamed graduation address in May.

Students attending the university had mixed feelings on the decision, and although the outcome was predictable, it is still disappointing to some seniors who wanted to walk on stage and receive their degree.

I knew was going to happen, because Wartburg just got shut down, Megan Stonewall a senior studying materials engineering said. I kind of saw coming, even though I didnt want it, because my senior design class is all medium people meeting up. So Im very sad. But I dont know how else to react to it, so Im just kind of chillin.

Even local business owners empathized with students about the change in their academic lives.

Everyones in a good mood and looking at celebrating achievements of their graduate, McCormick said. Just the other day I was thinking I feel terrible for the students.

The cancellation of commencement at Iowa State University, an annual celebration that brings thousands of people to the community, will be a hard hit for local businesses, especially hotels, local tourism officials said.

Kevin Bourke the president and CEO of Ames Convention and Visitors Bureau said that hotels generally bring at least a half of million dollars of revenue on that weekend alone.

Its tough to say; we can look at just hotel revenue, just people staying overnight is well over a half million dollars, but that doesnt count all the food and non-overnight visitors, Bourke said. So theres a lot of revenue that can be lost just in the celebration of graduation.

Law Enforcement

For local law enforcement, changes they have made are intended to keep the public, and local officers and deputies safe.

Were trying to do what we can to make sure we keep our people and the community healthy, Ames Police Cmdr. Jason Tuttle said. The last thing we want to do is have a couple of our people contract this virus we would be in a very difficult position if we had to quarantine.

If that unlikely scenario were to happen all of the agencies in Story County have been in constant communication and are ready to assist other agencies if needed, Story County Sheriff Paul Fitzgerald said.

To help slow the spread of the coronavirus, officers are sanitizing patrol vehicles, and hand sanitizier is readily available.

All the agencies are limiting their number of non-life threatening medical calls they respond to, and asking people being apprehended how they are feeling, and screening them to see whether they may or may not have COVID-19.

If theres any indication that (someone) might be a little warm or have a temperature when they get to jail, well have their temperature taken before getting in the facility. If its over 100 degrees they will be put into a quarantine cell where nurses will come and administer tests to the individual, Fitzgerald said.

If an officer is dispatched, they may be wearing extra protective equipment like gloves or masks and will be adhering to social distancing guidelines.

Medical Professionals

Restrictions on visitors by Mary Greeley were enhanced, minor surgeries have been postponed and a COVID-19 nurse line was launched.

Professionals at McFarland Clinic launched a triage COVID-19 nurse line to assist patients who are experiencing symptoms and have had known contact with someone who has been tested.

We created a coronavirus triage line, so if (community members) are worried about it they can call the (specific number) and go through a dedicated nurse who will help guide them to the next steps, Dan Fulton, McFarlands infectious disease specialist said. Those next steps will depend on how much of the infection were seeing in the community, where is the best place for that patient to get the care we need.

The line is open from 8 a.m until 5 p.m. daily and is: 515-500-677. The Iowa Department of Public Health has a similar line 2-1-1.

Hopes within McFarland are that calls to this direct line will eliminate COVID-19 questions to their clinics, allowing other patients not experiencing a cough, fever or shortness of breath to create an appointment, or speak to their medical provider, said Shelley Goecke, director of marketing and public relations for McFarland Clinic.

Looking forward

Despite the uncertainty of how long the changes were seeing will be in place, some say the community is handling the unprecedented situation well.

I think our community (has done) a phenomenal job in reacting to the whole pandemic, Dan Culhane, the president and CEO of the Ames Chamber of Commerce said.

Although peoples lives have been drastically changed, optimism about the future remains, and some believe Ames will be even stronger when the crisis passes.

All of us in Ames are going to experience a change in business, but we will bounce back. Ames is growing. There is a lot to do and see here for people in town and those traveling to Ames, Bonnie Alley, the general manager of Comfort Inn & Suites and Sleep Inn & Suites in Ames said.

See the rest here:
COVID-19: The week in review - Ames Tribune

By now, most people are aware of the importance of taking precautions to avoid spreading the Coronavirus to other people. But what about our pets?

First, the good news: Despite the widespread disease in the human population. There have been no reports of pets becoming ill with COVID-19," says Cassidy Rist. She teaches population health sciences at the Virginia-Maryland College of Veterinary Medicine at Virginia tech.

Also, there's no evidence to suggest that our pets can transmit this disease to us.

But she says, it possible, a person who has COVID-19 could contaminate a pet. And while dogs and cats dont become infected, the virus could remain on their bodies for a period of time. The CDC recommends people infected with COVID-19 practice isolation from their pets just like they would any other household member.

***Editor's Note: Radio IQ is a service of Virginia Tech.

This report, provided byVirginia Public Radio, was made possible with support from theVirginia Education Association.

Read more here:
COVID-19 and Pets - WVTF

Newsrooms have a long, not always proud tradition of gallows humor. The jokes and stories that get passed around are rarely the kind of things wed publish, especially when the people telling the stories have been in the business for a while.

One of the tame stories was from a former publisher who was, briefly, the suspect in a murder case. Authorities knew the victims body had been buried in a nearby nature reserve, and many killers will revisit locations like that. So investigators were monitoring the site.

Police noticed when he started showing up, routinely, near where the body was found. He never noticed them, and a brief investigation showed he wasnt connected to the case. After an arrest was made an investigator asked him what he was doing out there. It turns out the location was a good place to practice bird calls, which he was trying to learn.

Gallows humor has been getting a workout this past week. Im sure it has been in a lot more places than just newsrooms. Thats what happens when you know the worst of a bad situation is yet to come.

The speed with which people have reacted over the past couple weeks is remarkable. Its due to the fact medical professionals had a clear, understandable message and to people listening to that message. We dont yet know whether the actions came soon enough to really blunt this pandemic, but most people are doing what they can.

Still, life doesnt stop. Earlier this week we ran what we hope will be the first in a series of columns from Dr., Lorie Hickie, a veterinarian who moved back to Ottumwa in 2008. We know how much pets mean to Ottumwans. Pet stories and lottery winners always get a lot of traffic online. You dont work in our newsroom long before hearing veterans talk about how our website would probably crash if an area dog ever wins the lottery.

Hickie knows what shes talking about. She graduated from the Iowa State College of Veterinary Medicine in 2004. She was born and raised in Ottumwa, and lives here now with her husband, Chris, and their daughter, Amber.

Why debut something like this now? There are two fundamental reasons. One is that, frankly, we all need a break. Just writing about a subject other than this pandemic is a relief at times, and were sure people want to read about other things as well. And information about taking care of our pets accomplishes that quite nicely.

The other is that were still working on long-term goals. There will be a time when this crisis is over. There will be a time when we have to figure out what comes next. There will be a lot of work to do to get back to anything resembling what we think of as normal life. But that day will come, and this lays a little bit of a foundation for it.

Were glad to have Hickie on board as a monthly writer. And the reason goes back to some of the issues I touched on earlier. Theres a significant value to the community in having people with expertise being able to speak authoritatively on those subjects. In newspaper, its often our job to find those people and then get out of their way.

That has been our goal over the past couple weeks. No one in our newsroom is an expert on virology or medicine. Weve depended on those who are, and have tried to bring you their messages as clearly as possible. All I will add is one of my own:

Stay safe. Stay sane. Stay kind.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

See the original post here:
Finding the experts | Opinion - Ottumwacourier

Leadership from The Association for Animal Welfare Advancement (AAWA) the World Small Animal Veterinary Association (WSAVA), Shelter Medicine, and MightyVet to participate in first, worldwide webinar collaboration addressing COVID-19 and pets impacted in the crisis

SEATTLE, March 21, 2020 (GLOBE NEWSWIRE) -- Trupanion, the leader in medical insurance for pets, announced today that it is joining forces with The Association for Animal Welfare Advancement (AAWA), the membership organization exclusively for animal welfare, care and control leaders in the United States, Canada, and Australia. This partnership aims to provide veterinary and animal shelter professionals guidance on a community response during the current COVID-19 pandemic.

With the COVID-19 pandemic requiring communities to quarantine citizens, the care of impacted family pets has become a topic of concern for the entire veterinary community including, but not limited to, veterinary hospitals, veterinary educational institutions, and government and nonprofit animal shelters.

The first collaboration between Trupanion and AAWA will be a free, RACE approved, webinar for veterinary and animal shelter professionals offering guidance on community response to COVID-19, including considerations for those impacted by the crisis who have pets in their care.

We know that the veterinary community is on the frontline hearing from concerned pet owners about COVID-19 and their pets, said Jim Tedford, president and CEO for The Association for Animal Welfare Advancement and Certified Animal Welfare Administer (CAWA). At the same time, animal shelters play the important role as the community safety net for stray or relinquished animals within the scope of public health, law enforcement, public safety, and animal protection. By working together, united in a community response, our veterinary profession, including animal shelters, can help ease the minds of worried pet owners and provide sound guidance for pet owners to keep their pets safe as part of the family and out of shelters.

Using One Health as a driving philosophy, the webinar will take place on Wednesday, March 25 at 11:00 a.m. PDT (2:00 p.m. EDT) and will cover the latest information related to COVID-19 and its impact on our entire community. Covetrus, a global leader in animal-health technology and services, is generously hosting the webinar, which is expected to attract thousands of attendees.

Understanding how COVID-19 is transmitted, what to expect and how to bathe a pet exposed to a COVID-19 infected person, will enable veterinary professionals to help pets stay in homes and out of the sheltering system. This webinar will also provide clarity regarding conflicting information around personal protective equipment (PPE) requirements to help veterinary hospitals and shelters better anticipate the potential barriers and contingencies involved.

The webinar, moderated by Trupanions Chief Veterinary Officer, Dr. Steve Weinrauch, is the first collaboration of its kind, bringing together the leading organizations in human, animal, and environmental health in discussion of this latest pandemic.

By joining forces with these worldwide authorities in pet health and welfare, our goal is to provide the most current and useful information to the veterinary and sheltering community, said Dr. Steve Weinrauch, BVMS, MRCVS, chief veterinary officer at Trupanion and Founder of MightyVet an industry-wide platform to support veterinary professionals in their career and well-being. Trupanion is here to bring our members and pet owners across the world comfort in times of uncertainty, and that includes with Pandemics. We have been diligent in providing our members with the latest information around COVID-19 and how it impacts them as pet owners. Bringing these world leaders in pet health together to discuss these timely and important issues continues our commitment, not only to our members but also to the worldwide community. We look forward to spearheading this critical community effort with our esteemed colleagues.

This webinar will serve In Practice, Nonprofit and Government veterinary personnel as well as animal sheltering leadership.

Webinar Details

WHO: Dr. Steve Weinrauch, BVMS, MRCVS, chief veterinary officer, Trupanion, Founder, MightyVet; Jim Tedford, president and CEO for The Association for Animal Welfare Advancement and Certified Animal Welfare Administer (CAWA); Michael Lappin, DVM, PhD, DACVIM (SAIM), Chair, WSAVA One Health Committee; Julie Levy, DVM, PhD, DACVIM, DABVP (Shelter Medicine Practice), Fran Marino, Endowed Professor of Shelter Medicine, Maddies Shelter Medicine Program, University of Florida

Story continues

WHAT: Free, RACE approved webinar: Guidance for COVID-19 Community Response for Nonprofit, Government, and In Practice Veterinary Personnel

WHEN: Wednesday, March 25, 11:00 a.m. noon PDT

WHERE: There are two ways to access this webinar:

The first 3,000 veterinary professionals who pre-register at https://covetrus.zoom.us/webinar/register/WN_IpntPH6NQAmEOg0UKedSuA will be eligible for RACE credits and will join the webinar via the Zoom platform.

The webinar will also be streamed live at http://www.facebook.com/NotOneMoreVet . Please note that RACE credits are not available via the Facebook Live stream.

About TrupanionTrupanion is a leader in medical insurance for cats and dogs throughout the United States and Canada with over 500,000 pets enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. For more information, please visit trupanion.com.

About AAWASince 1970, The Association for Animal Welfare Advancement has been leading the conversation among animal welfare leaders. As the only membership organization dedicated exclusively to animal welfare, care and control professionals, The Association develops strong leaders, promotes standards of practice, and cultivates collaboration to advance the animal welfare profession with a united voice. For more information, please visit theaawa.org

About WSAVAThe WSAVA represents more than 200,000 veterinarians worldwide through its 113 member associations. Its core activities include the development of WSAVA Global Guidelines in key areas of veterinary practice, including pain management, nutrition and vaccination, and the provision of continuing education.

About MightyVetMightyVet is an initiative to support and evolve the veterinary ecosystem for the common good of pets, families and the veterinary professionals entrusted with their care. MightyVet provides veterinary professionals with free on-demand Continuing Education courses, mentorship from industry experts, virtual office hours for real-time feedback with Veterinary educators, and online resources for their day-to-day needs. Incubated by Trupanion, MightyVet is an industry-wide movement with participation and support from over 30 veterinary-related organizations. For more information, please visit mightyvet.org

Contact:

MediaMichael Nankmichael.nank@trupanion.com206.436.9825

InvestorsLaura Bainbridge, Head of Investor RelationsInvestorRelations@trupanion.com206.607.1929

Read more:
Trupanion Convenes Global Authorities in Animal Welfare for Exclusive Webinar for Veterinary Professionals to Help Communities Manage COVID-19 - Yahoo...

A classification of Dr. med. vet. Lena Horn / POLO+10

Every day new information, updates, emails and news about the 2019 Coronavirus Disease (COVID-19), which is caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2) are spread around the world. Most of them contain valuable information, but some also create myths and insecurity among us.

What we know for sure is that the COVID-19 virus is currently a big threat to our whole society. Worldwide the national governments are working closely together with the World Health Organization (WHO), infectious disease experts and e.g. the European Centre for Disease Control (ECDC), the Centers of Disease Prevention and Control (CDC), the World Organization for Animal Health (OIE) and national health authorities in order to learn more about COVID-19 and to slow the spread of the virus.

Why slow the spread? Because the health systems of the affected countries need to be able to function in an efficient way. This is only possible if the number of COVID-19 patients does not exceed the local medical resources and capacities. If all of us are cautious and respect the principles of social distancing, we can lower the number of newly infected people per day which results in flattening the curve (c.f. link 1).

But what does this mean in real life?

Stay home if you can, even if you dont feel sick or have any symptoms and avoid any physical social contact. Basically, quarantine yourself at home. If you do need to go outside be sure to respect the recommendations, laws or implementations issued by your local authorities. The WHO and e.g. ECDC and CDC are excellent resources regarding daily actions and precautions you can take in order to minimalize the risk of getting infected by and spreading the virus causing COVID-19.

The virus responsible is a betacoronavirus. Corona means crown and refers to the protein spikes on the lipid envelope of the virus. Coronavirus infections are common in humans and animals, and some strains are zoonotic (transmission between animals and humans are possible). Current evidence suggests that the SARS-CoV-2 responsible for COVID-19 has an animal source, but the predominant source of transmission seems to be human to human (via bodily secretions such as saliva and mucus droplets in a cough or sneeze of an infected person). Another possible route of virus transmission is the secondary route. This can occur by touching contaminated objects or surfaces and then touching your face (esp. mouth, nose or possibly eyes). In general, non-porous, smooth surfaces (e.g. plastic, metal) can transmit viruses better than porous, non-smooth materials (e.g. paper, pet fur).

At this point infectious disease experts and multiple international and domestic human and animal health organizations, such as the WHO, the OIE, the CDC and ECDC agree there is no evidence that animals become sick and also no evidence to suggest that companion animals can be a source of infection with SARS-CoV-2, including spreading COVID-19 to people. According to the OIE, further studies are needed to understand the role of animals in the spread of this human disease.

Currently, a general consensus is, that if you are not ill with COVID-19 you can handle and interact with your pet or horse as you normally would. Be aware that some countries have implemented strict rules regarding animal handling and care in order to minimize the possible spread of SARS-CoV-2 between owners, riders, handlers, caretakers etc. Always practice good general hygiene around your animals (clean equipment/tack, water/food bowls, stables, beds and toys on a regular basis) and be sure to keep their fur or coat well-groomed.

However, because animals can also spread other diseases to people and vice-versa, it is always advisable to observe basic principles of hygiene when coming into contact with animals (e.g. wash hands thoroughly with soap before and after contact).

If you are ill with COVID-19, you should be more precautious and limit the contact with animals until more is known about the role of animals and the SARS-CoV-2 outbreak. Daily activities such es feeding, grooming and playing should be performed by another member of the household. Some local shelters also offer to take care of your pet if you are tested positive. If your pet is a service animal or nobody else can take care of your animal the American Veterinary Medical Association recommends wearing a facemask, avoiding close contact with the animal (e.g. no kissing or food bowl sharing) and washing your hands before and after any contact with your pet.

Please be aware of the fact that the veterinarian community around the globe is highly impacted by the COVID-2019 pandemic. The national veterinarian medical associations and boards are closely working together with national and international agencies and organizations.

They are continuously adapting their strategies and updating their members about the measures to take during these difficult times. It is important to understand that, the authorities of many countries, have issued recommendations which might restrict the range of practicing veterinary medicine. If your animal gets sick or becomes injured, needs a refill of prescription medication or a special prescription diet food contact your veterinarian via phone or email and follow closely the instructions provided. Be aware that, due to a current shortage of personnel protection equipment (e.g. gowns, face masks, gloves), ventilators and medications for human patients, elective surgeries (surgeries that are scheduled in advance and that do not involve a medical emergency) are most likely to be postponed.

Currently the primary goals of the veterinarian community are to support the human medical health systems, to ensure the protection of the nations food supplies and to keep you and your animal(s) as well as the veterinarians and their staff healthy.

Links:

The rest is here:
COVID-19: What does the virus mean for us and the handling of our animals? - POLO+10 The Polo Magazine

A parasite known only to be hosted in North America by the Virginia opossum is infecting sea otters along the West Coast. A study from the University of California, Davis, elucidates the sometimes surprising and complex pathways infectious pathogens can move from land to sea to sea otter.

For the study, published in the journal Scientific Reports, researchers tested sea otters ranging from Southern California to Alaska for the presence of Sarcocystis neurona, a parasite and important cause of death in sea otters.

They were surprised to find several infected sea otters in the northern part of Vancouver Island in British Columbia, where Virginia opossums also known as the North American opossum are not known to live. They wondered: Could this parasite travel very long distances in water, or is there an additional unknown host for this pathogen?

To answer this question, the scientists examined spatial patterns and previous research into pathogen transmission, diet and movement of otters. Their results suggest the pathogen may be carried by water runoff from land to sea, where it can be concentrated through ocean movement and prey species, such as clams.

A related parasite, Toxoplasma gondii, is also known to kill sea otters. Decades of research by a consortium of scientists led by UC Davis School of Veterinary Medicine and the California Department of Fish and Wildlife traced that parasite to another land-based mammal wild and domestic cats near watersheds.

We know S. neurona kills sea otters, and we were pretty sure it comes from the land, but we didnt really know how this pathogen finds them, said lead author Tristan Burgess, a doctoral student in the lab of Christine Kreuder Johnson at the UC Davis One Health Institute at the time of the study. This new research suggests that there may be a long and complex transmission pathway, a little like the way Toxoplasma finds sea otters, but with a different cast of characters.

Most infections occurred in California and Washington, more so than Alaska and British Columbia. The study found that higher risks of exposure were associated with:

This study highlights risk factors for one species exposure to one parasite. But it also provides a better understanding of how parasites and infection can move from land to sea to marine mammals.

Seemingly unimportant species can be important in unexpected ways, Burgess said. We should also remember the value of marine mammals as sentinels, not just of the health of their marine habitat, but of nearby terrestrial environments, too.

S. neurona may be most familiar to horse owners, as the cause of equine protozoal myeloencephalitis, or EPM. UC Davis developed the diagnostic test for the disease in horses, and it has since been adapted for use in sea otters.

The study was supported by funding from the National Science Foundation Evolution and Ecology of Infectious Disease program, U.S. Geological Survey, U.S. Department of the Interior, U.S. Fish and Wildlife Service, Bureau of Ocean Energy Management, California Department of Fish and Wildlife, California Coastal Conservancy Sea Otter Tax Check-Off Fund, PG&E, Monterey Bay Aquarium and the UC Natural Reserve System.

See more here:
Sea Otters, Opossums and the Surprising Ways Pathogens Move From Land to Sea - UC Davis

Because the 2019 novel coronavirus is thought to spread mainly from person-to-person, Virginia Tech epidemiologist Charlotte Baker says everyone needs to be especially careful about minimizing the risk of exposure to yourself and others.

When you are in very close proximity to other people, it really does spread from droplets that are coming out of your lungs, said Baker. And you cant control that. We all breathe out different things out of our lungs all the time. Keeping a barrier between you and other people is really important, so we dont spread it further and faster.

Before coming to Virginia Tech, Dr. Baker was an Epidemic Intelligence Service (EIS) Officer at the United States Centers for Disease Control and Prevention, part of an elite corps that responds to national and international emergencies. At Virginia Tech she teaches public health students how to analyze and investigate health problems.

Older people tend to have some of the worst outcomes from it, but it doesnt mean that younger people dont have it too, she said. Younger people tend to be the ones that go from place to place and then spread it somewhere else. So we want to make sure people know you can be asymptomatic with it that means you dont have symptoms- and then you are touching and doing everything else, but you didnt know.

Background

Charlotte Baker is an assistant professor of epidemiology in the Department of Population Health Sciences at the Virginia Maryland College of Veterinary Medicine, located at Virginia Tech.

Video Interview with Dr. Baker

Schedule an interview

To schedule an interview with Charlotte Baker, contact Bill Foy by email, or by phone at 540-998-0288.

Our studio

Finding reliable experts for media interviews is especially important during this difficult time.Virginia Tech's television and radio studioscan broadcast live HD audio and video to networks, news outlets, and affiliates interviewing Virginia Tech faculty and staff. The university does not charge for use of its studios. Video is transmitted by LTN Global Communications; Skype, FaceTime, or similar products; or file sharing (Dropbox, Google Drive, We-Transfer, etc.). Radio interviews can be transmitted by ISDN, Comrex, phone, smartphone recording, or file sharing.

See original here:
Minimizing your risk of exposure to the coronavirus is key, expert says - Newswise

Travel and movement restrictions in Croatia are changing by the day - even by the hour - as the country fights to reign in COVID-19. 235 cases of coronavirus are currently confirmed in Croatia. Read on to find the latest travel (within, into and out of Croatia) information as of March 21, 2020.

TRAVEL AND MOVEMENT WITHIN CROATIA

New rules have been implemented by the Croatian government regarding civilian, vehicular and sea transport throughout the country.

Thefollowingcivilian movement restrictions are currently implemented across Croatia:

Gatherings of five or more people are banned

A two-metre distance must be kept between individuals outside of the home (both indoors and outdoors)

Loitering is prohibited in public areas including

* Streets

* Squares

* Rivieras

* Parks

* All other public surfaces on which a large number of people can gather

The following are still open

* Grocery stores* Grocery and hygienic product stores* Markets and fish markets* Specialized stores for medicine (pharmacies)* Specialized stores for veterinary-medical products* Agriculture-based pharmacies* Gas stations* Kiosks* Bakeries* Dry cleaners* Specialized stores with orthopedic and other assistance-based products* Specialized stores with equipment for children* Specialized stores with food for animals* Issuance of construction materials per retail order* Logistic and distribution centres for food, beverages and hygiene products* Wholesalers

The followingare closed

* All cultural establishments (museums, theaters, cinemas, libraries, reading rooms), exhibitions, shows and fairs* All customer service establishments (including cafs and restaurants), with the exception of food preparation and delivery services, accommodation services, and soup and student kitchens* All service establishments which entail close contact with customers (for example, hairdressers, beauty salons, barber shops, nail salons, massage parlors, saunas, swimming pools)* All sports competitions, organized trainings, gyms, sports centers, fitness and recreation centers* Childrens and other workshops and organized dance schools* Driving schools and language schools* Religious gatherings

Leaving the house should be kept to a minimumand only done when necessary, and in accordance with new rules.

The followingpublic transportrestrictions are currently implemented across Croatia:

* Public transportwithin and between cities and regions (excludingtaxis)

* International public transport

* All bus, tram and train transport

* Other public vehicles such as cable cars and funiculars

The following roadwayrestrictions are currently implemented across Croatia for civilian drivers:

* Novska jug

* Novska sjever

* Kozjak jug

* Prokljan sjever

* Dragani sjever

* Dragani jug

* Bava

* Ravna Gora

Follow the website of the Croatian Automobile Club, aka HAK (Croatia's equivalent to the USA's AAA or UK's AA) for full traffic information in English here.

The following sea travelrestrictions are currently implemented across Croatia:

* 310 Mali Losinj - (Unije) - Srakane Vele - Susak) and vice versa

* 311 Ilovik - Mrtvaka and vice versa

* 405 Rava - (Mala Rava - Veli I - Mali I) - Zadar and vice versa

* 415 Vrgada - Pakotane - (Biograd) and vice versa

* 501 Krpanj - Brodarica

* 505 (Vodice - Prvi epurine - Prvi Luka - Zlarin) - ibenik and vice versa

* 612 Komia - Bievo and vice versa

* 807 Suura - Lopud - Koloep - Dubrovnik

* Croatian and foreign nationals residing on the islands or in the Peljeac peninsula

* Vehicles belonging to or leased by island residents(adequately registeredper jurisdictional regulations)

* Public health employees

* Public service employees (including police officers, firefighters, armed forces, port authorities, post office staff, utility staff) and their official vehicles

* Store supply staff as approved by the Civil Protection Headquarters and their official vehicles as required

* Delivery service personnel and their vehicles

* Legal staff and their official vehiclesas approved by the Civil Protection Headquarters

For air travel information, check directly with airlines.

Croatia has nine civilian airports (see list below). Some airports offer information on their pages, but for specific air travel information (flight times, availability, cancellations, delays, refunds), check directly with airlines.

Anyonewho breaks restrictions is subject to fines and other potential punishment. Fines can reach up to120,000 HRK for repeat offenders.Police forces across the country will be monitoring streets and public areas to make sure rules are being followed. Maja Grba Bujevi, head of the Crisis Headquarters of the Ministry of Health,warned today that stricter measures are ahead if citizens disobey rules.

CROSS-BORDER TRAVEL

As of Tuesday, March 17, the European Union has closed its borders to all non-European Union citizens for a 30-day period. Travel within the EU is permitted or restricted on a country-by-country basis.

For travelto and from other EU countries from Croatia:

Croatia is allowing EU citizens to return to their countries of citizenship.Croatian citizens are allowed entry back into Croatia. EU citizens will be allowed entry to Croatia only inspecial circumstances (for example, health workers, researchers, diplomats, police officers, civilian safety teams, military personnel), as determined by the Croatian Institute of Public Health. Additional information regarding Croatia and its bordering countries can be found here.

Everyone(citizens and non-citizens) entering Croatia is subject to specificmeasures (which include isolation in a government facility or self-isolation), asrequiredby the Croatian Institute of Public Health.

For international travelto and from Croatia:

International bus and train lines have been stopped. International air travel is ongoingbut varies from case to case, so check flight information directly with airlines.

As of March 12, 2020, travellers to Croatia from specially-defined COVID-19-affected areas arerequired to spend 14 days in government quarantine facilities. Thedefined areas are

* China: Hubei province, including the city of Wuhan

* Germany:the County of Heinsberg in the state of North Rhine-Westphalia

* Iran

* Italy

* South Korea:the city of Daegu and the County of Cheongdo

The Croatian Ministry of Health has also implemented monitoring and self-isolation measures for travellersfrom any COVID-19-affected countries including

* Albania* Algeria* Andorra* Australia* Austria* Bahrain* Bangladesh* Belarus* Belgium* Brazil* Bulgaria* Cambodia* Cameroon* Canada* Chile* China (except region listed above)* Costa Rica* Cyprus* Czech Republic* Denmark* Ecuador* Egypt* Finland* France* Germany

* Greece

* Hong Kong* Hungary* Iceland* India* Indonesia* Iraq* Ireland* Israel* Japan* Lebanon* Liechtenstein* Luxembourg* Malaysia* Maldives* Malta* Monaco* Montenegro* Netherlands* New Zealand* North Macedonia* Norway* Pakistan* Peru* Philippines* Poland* Portugal* Romania* San Marino* Singapore* Slovakia* Slovenia* South Korea (except region listed above)* Spain* Sweden* Switzerland* Thailand* Turkey* Ukraine* United Arab Emirates* United Kingdom* United States of America* Vietnam

Travellers from these countries (even if theyshow noCOVID-19 symptoms)mustself-isolate for 14 days and contact the nearest epidemiologist for further instructions (which may include hospitalization if theyshow symptoms).

Alist of epidemiologist health institution contactsby Croatian county can be found here.

For non-EU citizens in Croatia, and for details about travelling in and out of the EU, consult your local embassies and specific government websites for travel and contact information.

The recommendation of the Croatian Ministry of Foreign and European Affairs is to delayany and all travels if possible.

Time Out (In) Croatia wishes everyone health, hope and healing.We will get through this!

See original here:
ALL YOU NEED TO KNOW: Travelling within, into and out of Croatia - March 21, 2020 - Time Out

DUBLIN, March 20, 2020 /PRNewswire/ -- The "Population Health Management Market by Component (Software, Services), Mode of Delivery (On-premise Mode of Delivery, Cloud-based Mode of Delivery), End User (Healthcare Providers, Healthcare Payers, Government Bodies)] - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global population health management market is projected to reach USD 39.4 billion by 2025 from USD 22.9 billion in 2020, at a CAGR of 11.5% during the forecast period.

Government mandates and support for healthcare IT solutions, increasing use of big data analytics, and the need to curtail the escalating healthcare costs are the key factors driving the growth of the population health management market. In addition, emerging economies (such as Brazil, Russia, India, South Korea, and China), increasing focus on personalized medicine, and rising focus on value-based medicine are expected to offer lucrative growth opportunities for market players during the forecast period. However, data breaches, lack of skilled analysts, and interoperability issues are adversely impacting the growth of this market.

The software segment accounted for the larger share of the population health management market, by component, in 2019

On the basis of component, the population health management market is segmented into software and services. The software segment accounted for the largest share of the population health management market in 2019. Technological advancements in IT solutions and big data analytics, growth of cloud computing, and increasing penetration of the Internet across the globe are some of the key factors driving the demand for software-based HCIT solutions. Moreover, the adoption of population health management software to coordinate care processes is expected to increase in the coming years owing to its ability to reduce readmissions, increase cost-effectiveness, and enhance patient engagement.

By mode of delivery, the on-premise mode of delivery segment accounted for the largest market share in 2019

Population health management solutions are delivered to end users through the on-premise and cloud-based modes of delivery. The on-premise solutions segment accounted for the larger market share in 2019. The advantages offered by the on-premise mode of delivery, and the ability to reuse existing servers and storage hardware are supporting its increased adoption in the population health management market.

By end user, the healthcare providers segment accounted for the largest market share in 2019

On the basis of end user, the population health management market is segmented into healthcare providers, healthcare payers, and other end users. In 2019, the healthcare providers segment accounted for the largest share of the population health management market. The advantages offered by PHM solutions, growing pool of patients, increasing load on hospitals to integrate and manage patient data in a more efficient way, and the growing need to improve the affordability and accessibility of healthcare services are propelling the growth of the PHM solutions market for healthcare providers.

APAC is the fastest-growing market for population health management.

The population health management market in the APAC is expected to witness the highest CAGR during the forecast period. The growth of the Asia Pacific population health management market is driven by the rising medical tourism, the implementation of new ICT guidelines in Japan, investments and reforms to modernize China's healthcare infrastructure, the rapidly growing healthcare industry in India, and the implementation of IT programs in Australia and New Zealand. In addition, government initiatives for the adoption of HCIT, the growing geriatric population, rising prevalence of chronic diseases, increasing healthcare expenditure, and the rising purchasing power of consumers are also expected to support market growth in this region.

Story continues

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Market Overview4.2 North America: Market, By Component & Country (2019)4.3 Population Health Management Market: Geographic Growth Opportunities

5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Government Mandates & Support for Healthcare IT Solutions5.2.1.2 Increasing Use of Big Data Analytics5.2.1.3 Need to Curtail Escalating Healthcare Costs5.2.2 Restraints5.2.2.1 Huge Investments in Infrastructure to Set Up A Robust PHM Program5.2.3 Opportunities5.2.3.1 Emerging Markets5.2.3.2 Rising Focus on Personalized Medicine5.2.3.3 Increasing Focus on Value-Based Medicine5.2.4 Challenges5.2.4.1 Data Breaches5.2.4.2 Lack of Data Management Capabilities and Skilled Analysts5.2.4.3 Interoperability Issues

6 Population Health Management Market, By Component 6.1 Introduction6.2 Software6.2.1 Software is the Largest Component Segment of the Market6.3 Services6.3.1 Increasing Adoption of PHM Solutions & Indispensable & Recurring Nature of Services to Drive Market Growth

7 Population Health Management Market, By Mode of Delivery 7.1 Introduction7.2 On-Premise Mode of Delivery7.2.1 On-Premise Mode of Delivery Segment Accounted for the Largest Market Share in 20197.3 Cloud-Based Mode of Delivery7.3.1 Cloud-Based Mode of Delivery Segment to Register the Highest Growth in the PHM Market Between 2020 & 2025

8 Population Health Management Market, By End User 8.1 Introduction8.2 Healthcare Providers8.2.1 Growing Need to Improve the Profitability of Healthcare Operations is Driving the Use of PHM Solutions Among These End Users8.3 Healthcare Payers8.3.1 Increased Focus on Outcome-Based Payment Models has Driven the Demand for PHM Solutions Among Healthcare Payers8.4 Other End Users

9 Population Health Management Market, By Region 9.1 Introduction9.2 North America9.2.1 US9.2.1.1 The US is the Largest Market for Population Health Management Solutions9.2.2 Canada9.2.2.1 Deployment of Digital Health Initiatives is Boosting Market Growth in Canada9.3 Europe9.3.1 Germany9.3.1.1 Germany Dominates the European Population Health Management Market9.3.2 UK9.3.2.1 Increasing Public-Private Initiatives to Support the Adoption of PHM Solutions in the Country9.3.3 France9.3.3.1 Rising Geriatric Population and the Increasing Patient Volume for Various Chronic and Age-Related Conditions to Drive Market Growth9.3.4 Italy9.3.4.1 Government Initiatives to Support Market Growth in Italy9.3.5 Spain9.3.5.1 Increasing Adoption of PHM Solutions to Support Market Growth in Spain9.3.6 Rest of Europe9.4 Asia Pacific9.4.1 Japan9.4.1.1 Japan Accounted for the Largest Share of the APAC PHM Market in 20199.4.2 China9.4.2.1 Strong Government Support in China is Driving the PHM Market9.4.3 India9.4.3.1 Growing Volume of Patient Data Generated Within Healthcare Systems to Propel the Market for PHM Solutions in India9.4.4 Rest of Asia Pacific (RoAPAC)9.5 Rest of the World9.5.1 Latin America9.5.1.1 Brazil, Argentina, and Mexico are Emerging Healthcare Markets in Latin America9.5.2 Middle East & Africa9.5.2.1 Increasing Investments in Modernizing Healthcare Systems are Propelling Market Growth

10 Competitive Landscape 10.1 Introduction10.2 Competitive Leadership Mapping (Overall Market)10.2.1 Visionary Leaders10.2.2 Innovators10.2.3 Dynamic Differentiators10.2.4 Emerging Companies10.3 Competitive Scenario

11 Company Profiles 11.1 Cerner Corporation11.2 Epic Systems Corporation11.3 Koninklijke Philips11.4 I2I Population Health11.5 Health Catalyst11.6 Optum (Part of Unitedhealth Group)11.7 Enli Health Intelligence11.8 Eclinicalworks11.9 Allscripts Healthcare Solutions11.1 IBM Corporation11.11 Healthec, LLC11.12 Medecision11.13 Arcadia11.14 Athenahealth11.15 Cotiviti (Verscend Technologies)11.16 Nextgen Healthcare Inc.11.17 Conifer Health Solutions11.18 SPH Analytics11.19 Lightbeam Health Solutions11.20 Innovaccer

For more information about this report visit https://www.researchandmarkets.com/r/q02un0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/population-health-management-industry-forecast-to-2025-a-39-billion-landscape-opportunity-301027444.html

SOURCE Research and Markets

See more here:
Population Health Management Industry, Forecast to 2025: A $39+ Billion Landscape Opportunity - Yahoo Finance

Verified Market Research recently published a research report titled, Personalized Medicine Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Personalized Medicine market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=BCC&utm_medium=002

Personalized Medicine Market Leading Players:

Personalized Medicine Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Personalized Medicine market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Personalized Medicine market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Personalized Medicine market.

Market Segments: This part of the report discusses about product type and application segments of the Personalized Medicine market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Personalized Medicine market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Personalized Medicine market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Forecast, Personalized Medicine Market Growth, Personalized Medicine Market Analysis

Read more from the original source:
Personalized Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - NJ MMA News

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients.

The study analyzed more than 1,000 pancreatic cancer patients enrolled in PanCAN's Know Your Tumor precision medicine service, powered by Perthera, and found those patients who received matched therapies following molecular profiling of their tumor, using the Perthera Platform, saw an overall survival benefit of one year longer than those who did not.

Pancreatic cancer is the world's toughest cancer with an overall five-year survival rate of just 10 percent. It is currently the third leading cause of cancer-related death in the U.S., underscoring the urgent need for new treatment options and research discoveries in this space.

When PanCAN's Know Your Tumor service was started with Perthera in 2014, key precision medicine resources such as molecular profiling were rarely offered to patients with pancreatic cancer because many doctors assumed there wasn't anything actionable to be found. The study showed that approximately 25 percent of pancreatic cancer patients have an actionable alteration. It also underscores the significance of the most recent National Comprehensive Cancer Network (NCCN) guidelines that state that every patient with pancreatic cancer should get testing - both molecular profiling of their tumor and germline (genetic) testing for alterations they were born with.

The results of this study will help re-write the future for cancer patients for years to come, said Gary Gregory, CEO & President, Perthera, Inc. Increasing patient survival is the cornerstone of the work that PanCAN has spearheaded with Perthera across the U.S. This study clearly proves that, by utilizing precisely matched therapies provided by molecular profiling, along with Therapeutic Intelligence and a Molecular Tumor Board, patients with pancreatic cancer have experienced significant increases in both overall and progression-free survival.

This is critical news for pancreatic cancer patients. Every tumor is different and through this study, we know that patients who get tested and receive treatment based on their tumor's biological characteristics are living longer, said Lynn Matrisian, PhD, MBA, Chief Science Officer at PanCAN and an author on the paper. It is a strong reminder to healthcare professionals to offer tumor profiling to all their pancreatic cancer patients. And it will further provide an incentive to the scientific community to pursue new targeted treatments for even more pancreatic cancer patients.

Several of the molecularly-matched therapies given have now been FDA approved for patients with pancreatic cancer based on select biomarkers. Adopting molecular profiling into routine practice will be critically important to making sure these patients do not miss out on life-extending opportunities that can now be covered by insurance. These real-world outcomes suggest that the adoption of a precision medicine platform can have a substantial impact on survival in patients with pancreatic cancer, and that molecularly-guided treatments targeting oncogenic drivers and the DNA damage repair pathway warrant further prospective evaluation, said Mike Pishvaian, MD, PhD, Perthera's Chief Medical Officer GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Johns Hopkins Medicine.

PanCAN recommends that all pancreatic cancer patients undergo testing of both their tumor tissue (molecular profiling) and blood or saliva for genetic (germline) changes to determine if they have an actionable alteration and to identify treatment options for that patient. Patients can enroll in PanCAN's free Know Your Tumor precision medicine service today, as well as receive free, in-depth, and personalized resources and information on the disease through PanCAN's Patient Central.

The Perthera Platform has been proven to capitalize upon actionable alterations and improve patient outcomes across numerous, peer reviewed clinical publications. The Perthera Platform, which has been used by over 250 cancer treatment sites across the U.S., captures a patient's entire medical and treatment history, as well as their multi-omic molecular profile, to create a personalized treatment plan, that enable physicians to effectively harness the power of precision medicine.

More here:
New Research Reveals Pancreatic Cancer Patients Who Receive Precision Medicine Live An Average Of One Year Longer Than Those Who Do Not #47579 - New...

President Donald Trump has repeatedly said that the US is working to develop a vaccine for Covid-19, the disease caused by the novel coronavirus, as quickly as possible. But one of his own administrations policies appears to be standing in the way of at least one scientist.

According to a report by the Washington Posts Amy Goldstein, Kim Hasenkrug, an immunologist at the National Institutes of Healths Rocky Mountain Laboratories in Montana, wants to test potential treatments for Covid-19 in mice with humanized lungs. But as the Post first reported, the work is being held up by officials at the Department of Health and Human Services due to a 2019 ban on NIH scientists using donated fetal tissue from abortions in their research.

While fetal tissue isnt typically used to develop actual therapies or treatments, it has one particularly key use for researchers: the ability to create mice with human tissue suitable for medical testing. Mice, generally, have similar immune systems to humans, making them particularly useful for early medical testing.

Humanized mice have been key to developing several important medical treatments for diseases like the Zika virus or HIV/AIDS, which was Hasenkrugs previous research focus. The calculation is simple. You cant test certain treatments without humanized mice, and you cant get humanized mice without fetal tissue.

There are, of course, many avenues of research using other kinds of tissue, but fetal cells can rapidly divide, grow, and adapt to new environments in ways that make them the gold standard for some disease research. And in other research areas, we dont yet know if there is anything that could substitute, R. Alta Charo, professor of law and bioethics at the University of Wisconsin at Madison, wrote in the New England Journal of Medicine in 2015.

And as the Posts Goldstein noted, scientists have already shown that humanized mice could make good test subjects for coronavirus treatments specifically:

Just months ago, before the new coronavirus began to infect people around the world, other U.S. scientists made two highly relevant discoveries. They found that specialized mice could be transplanted with human fetal tissue that develops into lungs the part of the body the new coronavirus invades. These humanized mice, they also found, could then be infected with coronaviruses to which ordinary mice are not susceptible closely related to the one that causes the new disease, Covid-19.

Outside researchers have offered the mice to Hasenkrug for coronavirus research. But so far, Hasenkrug and other government researchers havent been allowed to obtain the mice they need to perform testing, the Post reported, thanks to a June 2019 HHS directive banning fetal tissue research for those employed by the government.

Caitlin Oakley, a HHS spokesperson, told the Post that no decision has been made about Hasenkrugs request. A separate HHS spokesperson confirmed that in a statement to Vox.

The spokesperson also pointed to an HHS statement from last June detailing the administrations policy on fetal tissue research. Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trumps administration, reads the statement.

Hasenkrug, and the potentially millions of Americans who may benefit from his research, now find themselves caught in a deeply divisive political issue thats been years in the making.

The US government had funded fetal tissue research efforts since the 1950s and for nearly as long, anti-abortion activists have opposed the practice.

In the Trump era, they finally found an administration ready to listen.

In 2018, the US government spent $115 million on about 173 research projects utilizing fetal tissue, a third of which were devoted to developing therapies for HIV/AIDS.

Research using fetal tissue has led to the development of vaccines such as those for polio, rubella, and measles, the International Society for Stem Cell Research (ISSCR) said in a statement last September. Fetal tissue is still helping advance science, with research underway using cells from fetal tissue to evaluate conditions including Parkinsons disease, ALS, and spinal cord injury. Fetal tissue is also necessary for the development of potential treatments for Zika virus and HIV/AIDS.

But anti-abortion activists argue it incentivizes abortion providers to perform more abortions in order to procure more tissue they could sell to third-party companies, which then provide the tissue directly to researchers. Fetal tissue procurement has been heavily regulated since enactment of the NIH Revitalization Act of 1993, which states that profits cannot be made in the transfer or acceptance of fetal tissue for research purposes.

That hasnt stopped anti-abortion activists from continuing to call into question the ethics of abortion providers or procurement companies. In 2000, the anti-abortion rights group Life Dynamics seemingly began the practice of releasing false or deceptively edited videos targeting the fetal tissue sales process. The main source in their videos was found to be not credible.

The George W. Bush administration did not take action against fetal tissue research, instead enacting restrictions on stem cell research derived from embryos in an August 2001 executive order. Those restrictions were later rolled back by an executive order from President Barack Obama in 2009.

More recently, the anti-abortion rights group Center for Medical Progress, run by activist David Daleiden, infamously released heavily edited videos appearing to show a Planned Parenthood employee negotiating prices for fetal tissue, and CMP accused the abortion care provider of illegally profiting from sales.

The videos caught the attention of Republican lawmakers. Investigations by the House Energy and Commerce, House Judiciary, and Oversight and Government Reform committees found no wrongdoing. Further investigations into Planned Parenthood and fetal tissue transfer proceeded with the creation of the Select Investigative Panel on Infant Lives in October 2015, chaired by Rep. Marsha Blackburn (R-TN), leading to $1.59 million in spending and a 471-page final report making numerable anti-abortion recommendations.

Among those requests was a call for the government to ban fetal tissue research by government scientists, which Barack Obamas administration, which favored the practice, ultimately ignored.

Democrats on the committee released their own report, disputing the conclusions of their Republican colleagues. At the end of their crusade, the conclusion was undeniable: There was no wrongdoing on behalf of fetal tissue researchers, including Advanced Bioscience Resources, or anyone else in the fetal tissue research space, said Rep. Jan Schakowksy (D-IL), who served as the ranking Democrat on the select committee, in a statement to Rewire.News in October 2018.

Anti-abortion activists saw an opportunity to advance their agenda on fetal tissue research when President Donald Trump won election in 2016, but it took a conservative media freakout in 2018 to enact new restrictions.

Over the summer of 2018, conservative media focused on several transactions by Advanced Bioscience Resources, a company that procured fetal tissue from abortion providers and shipped it to researchers for use. ABR was also one of the subjects of the 2015 select committee investigation.

HHS decided to cancel the governments contract with ABR in late September 2018 and began a review of the agencys rules and processes for procuring fetal tissue for research. That review concluded last summer, with HHS announcing in June that it would ban any fetal tissue studies by in-house NIH scientists, like Hasenkrug. It also introduced strict paperwork requirements for any outside scientists conducting research funded by the government.

The decision came as welcome news to anti-abortion activists. The language is trying to hold an ethical standard for the research proposals and the research that might be done. The policy is not just about science. Its also about ethics, David Prentice, vice president and research director at the anti-abortion Charlotte Lozier Institute, told Science magazine last July.

For his part, Hasenkrug has reportedly asked the Trump administration several times for permission to begin working with UNCs humanized mice for a coronavirus cure, but is still waiting on permission. Per the Post:

On Feb. 19, two people said, Hasenkrug wrote to a senior NIH official, asking for permission to use those mice and run experiments related to covid-19. He eventually was told that his request had been passed on to senior HHS officials.

Since then, he has written repeatedly to NIH, laying out in greater detail the experiments he wants to undertake and why several alternatives to the fetal tissue-implanted mice would not be as useful. In one appeal to NIH, Hasenkrug wrote that the mice he was offered are more than a year old and have a relatively short time remaining to live, so they should be used quickly, according to Kerry Lavender, a Canadian researcher familiar with the correspondence.

Hasenkrugs request has reportedly been forwarded to the White House Domestic Policy Council, which is chaired by Trump himself, but the government has not made a decision on the research as of yet.

Read more here:
Coronavirus treatment research is delayed by Trumps ban on the use of fetal tissue - Vox.com

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Even in the midst of the COVID-19 pandemic, cancer care must go on, but changes may need to be made in the way some care is delivered.

"We're headed for a time when there will be significant disruptions in the care of patients with cancer," said Len Lichtenfeld, MD, deputy chief medical officer of the American Cancer Society (ACS), in a statement. "For some it may be as straightforward as a delay in having elective surgery. For others it may be delaying preventive care or adjuvant chemotherapy that's meant to keep cancer from returning or rescheduling appointments."

Lichtenfeld emphasized that cancer care teams are going to do the best they can to deliver care to those most in need. However, even in those circumstances, it won't be life as usual. "It will require patience on everyone's part as we go through this pandemic," he said.

"The way we treat cancer over the next few months will change enormously," writes a British oncologist in an article published in the Guardian.

"As oncologists, we will have to find a tenuous balance between undertreating people with cancer, resulting in more deaths from the disease in the medium to long term, and increasing deaths from COVID-19 in a vulnerable patient population. Alongside our patients we will have to make difficult decisions regarding treatments, with only low-quality evidence to guide us," writes Lucy Gossage, MD, consultant oncologist at Nottingham University Hospital, UK.

The evidence to date (from reports from China in Lancet Oncology) suggests that people with cancer have a significantly higher risk of severe illness resulting in intensive care admissions or death when infected with COVID-19, particularly if they recently had chemotherapy or surgery.

"Many of the oncology treatments we currently use, especially those given after surgery to reduce risk of cancer recurrence, have relatively small benefits," she writes.

"In the current climate, the balance of offering these treatments may shift; a small reduction in risk of cancer recurrence over the next 5 years may be outweighed by the potential for a short-term increase in risk of death from COVID-19. In the long term, more people's cancer will return if we aren't able to offer these treatments," she adds.

One thing that can go on the back burner for now is routine cancer screening, whichcan bepostponed for now in order to conserve health system resources and reduce contact with healthcare facilities, says the ACS.

"Patients seeking routine cancer screenings should delay those until further notice," said Lichtenfeld. "While timely screening is important, the need to prevent the spread of coronavirus and to reduce the strain on the medical system is more important right now."

But as soon as restrictions to slow the spread of COVID-19 are lifted and routine visits to health facilities are safe, regular screening tests should be rescheduled.

The American Society of Clinical Oncology (ASCO) has issued new guidance on caring for patients with cancer during the COVID-19 outbreak.

First and foremost, ASCO encourages providers, facilities, and anyone caring for patients with cancer to follow the existing guidelines from the Center for Disease Control and Prevention (CDC) when possible.

ASCO highlights the CDC's general recommendation for healthcare facilities that suggests "elective surgeries" at inpatient facilities be rescheduled if possible, which has also been recommended by the American College of Surgeons.

However, in many cases, cancer surgery is not elective but essential, it points out. So this is largely an individual determination that clinicians and patients will need to make, taking into account the potential harms of delaying needed cancer-related surgery.

Systemic treatments, including chemotherapy and immunotherapy, leave cancer patients vulnerable to infection, but ASCO says there is no direct evidence to support changes in regimens during the pandemic. Therefore, routinely stopping anticancer or immunosuppressive therapy is not recommended, as the balance of potential harms that may result from delaying or interrupting treatment versus the potential benefits of possibly preventing or delaying COVID-19 infection remains very unclear.

Clinical decisions must be individualized, ASCO emphasized, and suggestedthe following practice points be considered:

For patients already in deep remission who are receiving maintenance therapy, stopping treatment may be an option.

Some patients may be able to switch from IV to oral therapies, which would decrease the frequency of clinic visits.

Decisions on modifying or withholding chemotherapy need to consider both the indication and goals of care, as well as where the patient is in the treatment regimen and tolerance to the therapy. As anexample, the riskbenefit assessment for proceeding with chemotherapy in patients with untreated extensive small-cell lung cancer is quite different than proceeding with maintenance pemetrexed for metastatic nonsmall cell lung cancer.

If local coronavirus transmission is an issue at a particular cancer center, reasonable options may include taking a 2-week treatment break or arranging treatment at a different facility.

Evaluate if home infusion is medically and logistically feasible.

In some settings, delaying or modifying adjuvant treatment presents a higher risk of compromised disease control and long-term survival than in others, but in cases where the absolute benefit of adjuvant chemotherapy may be quite small and other options are available, the risk of COVID-19 may be considered an additional factor when evaluating care.

For patients who are candidates for allogeneic stem cell transplantation, a delay may be reasonable if the patient is currently well controlled with conventional treatment, ASCO comments. It also directs clinicians to follow the recommendations provided by the American Society of Transplantation and Cellular Therapy and from the European Society for Blood and Marrow Transplantation regarding this issue.

Finally, there is also the question of prophylactic antiviral therapy: Should it be considered for cancer patients undergoing active therapy?

The answer to that question is currently unknown, says ASCO, but "this is an active area of research and evidence may be available at any time."

For more from Medscape Oncology, join us on Twitter and Facebook.

See the article here:
Disruptions in Cancer Care in the Era of COVID-19 - Medscape

As a partner, you will help the Arthritis Foundation provide life-changing resources, science, advocacy and community connections for people with arthritis, the nations leading cause of disability. Join us today and help lead the way as a Champion of Yes.

Our Trailblazers are committed partners ready to lead the way, take action and fight for everyday victories. They contribute $2,000,000 to $2,749,000

Our Visionary partners help us plan for a future that includes a cure for arthritis. These inspired and inventive champions have contributed $1,500,00 to $1,999,999.

Our Pioneers are always ready to explore and find new weapons in the fight against arthritis. They contribute $1,000,000 to $1,499,999.

Our Pacesetters ensure that we can chart the course for a cure for those who live with arthritis. They contribute $500,000 to $999,000.

Our Signature partners make their mark by helping us identify new and meaningful resources for people with arthritis. They contribute $250,000 to $499,999.

Our Supporting partners are active champions who provide encouragement and assistance to the arthritis community. They contribute $100,000 to $249,999.

Read more:
Arthritis Foundation | Symptoms Treatments | Prevention Tips ...

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

Story continues

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

View original content:http://www.prnewswire.com/news-releases/visiongain-report-global-rheumatoid-arthritis-drugs-market-estimated-to-grow-at-a-cagr-of-0-6-in-the-second-half-of-the-forecast-period-301022961.html

SOURCE Visiongain

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - Yahoo...

Report Description

A recent market intelligence report that is published by Data Insights Partner on theglobal Rheumatoid Arthritis marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and international Rheumatoid Arthritis market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and global Rheumatoid Arthritis market over the short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of global Rheumatoid Arthritis market is offered. In accordance with the report, the global Rheumatoid Arthritis market is projected to expand at a CAGR of 5% over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Rheumatoid arthritis is an autoimmune disease which can cause inflammation and pain in joints throughout the body. There are several types of diagnosis available for rheumatoid arthritis such as rheumatoid factor test, antinuclear antibody test, C-reactive protein test, erythrocyte sedimentation rate etc. Although there is no specific treatment available for cure of rheumatoid arthritis, some treatment help the patients to control this chronic disorder.

The global Rheumatoid Arthritis market is primarily driven by the increasing new cases of rheumatoid arthritis across worldwide. Around 1% of the world population has been suffering from rheumatoid arthritis whereas almost 3 new cases of rheumatoid arthritis per 10,000 population per year has been documented in 2018. In addition to increasing new cases of rheumatoid arthritis across worldwide, high diagnosis and treatment rate would likely to drive the global Rheumatoid Arthritis Market in the upcoming future. On the contrary, the stringent regulatory landscape and side effects of medications would likely to hamper the growth of the global Rheumatoid Arthritis market during the forecast period.

However, increasing expenditure in research and development, strategic alliance among key players and ongoing clinical trials may provide the global Rheumatoid Arthritis Market an opportunity to propel during the forecast period. For instance, Abbvie, a market leader in the global Rheumatoid Arthritis market acquired another pharmaceutical stalwart Allergan by US$ 63 Bn in June 2019. The acquisition would likely to boost the market position of Abbvie in the global Rheumatoid Arthritis market in upcoming future.

Request Preview of Report as Sample before Purchasing (For More Precedence Use Corporate email ID) :https://datainsightspartner.com/request-for-sample?ref=43

Segment Covered:

This market intelligence report on the global Rheumatoid Arthritis market encompasses market segments based on drug type and distribution channel. On the basis of drug type, the sub-market is categorized into NSAIDs, Analgesics, DMARDs, Glucocorticoids, Biologics, and Others. Based on distribution channel, the global Rheumatoid Arthritis market has been segregated into hospital pharmacies, retail pharmacies and drug stores and online sales. By Geography, the global Rheumatoid Arthritis market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company etc. have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Rheumatoid Arthritis related investment & spending and developments by major players of the market are tracked in this global report.

Request for Report TOC:https://datainsightspartner.com/report/rheumatoid-arthritis-market/43#content

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Find more research reports onHealthcare Industry,By Data Insights Partner

Salient Features:

This study offers comprehensive yet detailed analysis of the Rheumatoid Arthritis market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2018 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the world Rheumatoid Arthritis market is done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overvie

Leading market players covered this report comprise names such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company. and among others

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market for Rheumatoid Arthritis caters to the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors for Rheumatoid Arthritis market. The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in the Rheumatoid Arthritis market

vIdentification of key factors driving investment opportunities in the Rheumatoid Arthritis market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events

vIdentify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects

vIdentify key strengths and weaknesses of important market participants

Request for Report Analysis:https://datainsightspartner.com/report/rheumatoid-arthritis-market/43

See the original post:
RHEUMATOID ARTHRITIS MARKET size Surge at a Robust Pace in Terms of Revenue over 2027 - Packaging News 24

The right kind of inflammation is essential to your body's healing system. But chronic inflammation can be a problem.

Published: April, 2020

The saying "too much of a good thing" applies to much of life, but especially to inflammation.

"People think inflammation needs to be stomped out at all times, but it plays an essential role in healing and injury repair to keep your body safe and healthy," says Dr. Robert H. Shmerling, medical editor of Understanding Inflammation from Harvard Health Publishing and an associate professor of medicine at Harvard Medical School. "Some inflammation is good. Too much is often bad. The goal is to recognize when inflammation is simply doing its job, and when it can potentially cause problems."

Signs of inflammation are like a car's dashboard engine light. It tells you that something is wrong. But your response is not to take out the bulb, because that's not the problem. Instead, you look at what caused the light to turn on. "It's the same with inflammation," says Dr. Shmerling. "It's telling you that something bigger is going on that requires attention."

There are two types of inflammation: acute and chronic. People are most familiar with acute inflammation. This is the redness, warmth, swelling, and pain around tissues and joints that occurs in response to an injury, like when you cut yourself. When the body is injured, your immune system releases white blood cells to surround and protect the area.

"Acute inflammation is how your body fights infections and helps speed up the healing process," says Dr. Shmerling. "In this way, inflammation is good because it protects the body." This process works the same if you have a virus like a cold or the flu.

In contrast, when inflammation gets turned up too high and lingers for a long time, and the immune system continues to pump out white blood cells and chemical messengers that prolong the process, that's known as chronic inflammation. "From the body's perspective, it's under consistent attack, so the immune system keeps fighting indefinitely," says Dr. Shmerling.

When this happens, white blood cells may end up attacking nearby healthy tissues and organs. For example, if you are overweight and have more visceral fat cells the deep type of fat that surrounds your organs the immune system may see those cells as a threat and attack them with white blood cells. The longer you are overweight, the longer your body can remain in a state of inflammation.

Research has shown that chronic inflammation is associated with heart disease, diabetes, cancer, arthritis, and bowel diseases like Crohn's disease and ulcerative colitis.

Yet, because chronic inflammation can continue for a long time, it's not easy to know its exact impact. "It's a chicken-and-egg scenario," says Dr. Shmerling. "Does chronic inflammation increase the risk of these ailments, or is it a byproduct? It is not always clear."

Here are some other steps you can take to prevent and reduce chronic inflammation:

Most of the time, you don't need to worry too much about acute inflammation, says Dr. Shmerling. You can take an over-the-counter pain reliever to help relieve symptoms, or apply cold compresses to reduce swelling. "Otherwise, it is usually best to let the inflammation do its work to help with healing," says Dr. Shmerling.

Of course, the cause of acute inflammation may need treatment. For example, a bacterial infection may require antibiotics, so if you have a fever or significant symptoms such as severe pain or shortness of breath see your doctor.

Chronic inflammation is trickier to deal with. The problem is that chronic inflammation is often "invisible," since it does not show telltale physical signs the way acute inflammation does.

So how can you prevent or reduce inflammation you cannot necessarily see or feel?

The only way to detect chronic inflammation is to have an evaluation by your doctor. He or she will review your symptoms, perform a physical exam, and perhaps check your blood for signs of inflammation. (See "A test for inflammation.")

Otherwise, the best approach is to prevent conditions related to chronic inflammation. "It goes back to the basics: maintaining a healthy weight, choosing a good diet, getting plenty of sleep, and exercising regularly," says Dr. Shmerling.

How do you know if you have chronic inflammation? A blood test measures a protein produced by the liver, C-reactive protein (CRP), which rises in response to inflammation. A CRP level between 1 and 3 milligrams per liter of blood often signals a low, yet chronic, level of inflammation. The erythrocyte sedimentation rate is another blood test for inflammation. It is used for people with inflammatory conditions, like rheumatoid arthritis.

Diet and exercise have an especially strong impact on managing chronic inflammation since they both also can help control weight and improve sleep.

The evidence is not clear that a specific type of diet can prevent chronic inflammation. However, certain foods are associated with either promoting or inhibiting the inflammatory response. These foods also are linked to a lower risk of problems related to chronic inflammation, such as heart disease, weight gain, and cancer.

For instance, cut back or eliminate foods high in simple sugars like soda, fruit juices with added sugars, sports drinks, processed meat, and refined carbs like white bread and pasta. "These foods can spike blood sugar levels, which can lead to overeating and weight gain," says Dr. Shmerling.

Also, eat more foods high in the antioxidants known as polyphenols, which can lower inflammation. Examples include all types of berries, cherries, plums, red grapes, onions, turmeric, green tea, and dark green leafy vegetables like spinach and kale.

Regular exercise can help protect against conditions linked with chronic inflammation, especially heart disease and obesity. A 2017 study in Brain, Behavior, and Immunity found that just 20 minutes of moderate-intensity exercise (in this case, walking on a treadmill) can have an anti-inflammatory effect.

Image: Mingirov/Getty Images

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

The rest is here:
Understanding acute and chronic inflammation - Harvard Health